1. Granel, Brigitte, Allanore, Yannick, Chevillard, Christophe, Kahan, André, Dessein, Alain. 2006. IL13RA2 gene polymorphisms are associated with systemic sclerosis. In The Journal of rheumatology, 33, 2015-9. doi:. https://pubmed.ncbi.nlm.nih.gov/16981293/
2. Chong, Siao Ting, Tan, Khee Ming, Kok, Catherine Y L, Lam, Paula Y P, Ngeow, Joanne. . IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma. In The Journal of clinical endocrinology and metabolism, 104, 5573-5584. doi:10.1210/jc.2019-00040. https://pubmed.ncbi.nlm.nih.gov/31290966/
3. Verstockt, Bram, Verstockt, Sare, Creyns, Brecht, Ferrante, Marc, Breynaert, Christine. 2019. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. In Alimentary pharmacology & therapeutics, 49, 572-581. doi:10.1111/apt.15126. https://pubmed.ncbi.nlm.nih.gov/30663072/
4. Li, Xiaoou, Xiao, Xiong, Wang, Yi, Zhang, Yang, Zhang, Liwei. 2024. Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas. In Cancers, 16, . doi:10.3390/cancers16010228. https://pubmed.ncbi.nlm.nih.gov/38201655/
5. Wang, Mimi, Yao, Rongrong, Wang, Yanhong. 2020. Silencing of IL13RA2 promotes partial epithelial-mesenchymal transition in hepatocellular carcinoma via ERK signaling pathway activation. In FEBS open bio, 10, 229-236. doi:10.1002/2211-5463.12774. https://pubmed.ncbi.nlm.nih.gov/31823484/
6. Sattiraju, Anirudh, Solingapuram Sai, Kiran Kumar, Xuan, Ang, Debinski, Waldemar, Mintz, Akiva. . IL13RA2 targeted alpha particle therapy against glioblastomas. In Oncotarget, 8, 42997-43007. doi:10.18632/oncotarget.17792. https://pubmed.ncbi.nlm.nih.gov/28562337/
7. Shibasaki, Noboru, Yamasaki, Toshinari, Kanno, Toru, Ogawa, Osamu, Kamba, Tomomi. 2015. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. In PloS one, 10, e0130980. doi:10.1371/journal.pone.0130980. https://pubmed.ncbi.nlm.nih.gov/26114873/